Cargando…

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens

BACKGROUND: Neurocognitive disorders due to human immunodeficiency virus (HIV) remain highly prevalent, specifically mild forms despite effective antiretroviral therapy (ART). Dolutegravir-based regimens are the first line of treatment for adult HIV-positive patients. Controversies exist regarding t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodrigues, Janine, Lowton, Karishma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AOSIS 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546244/ https://www.ncbi.nlm.nih.gov/pubmed/37795459 http://dx.doi.org/10.4102/sajpsychiatry.v29i0.2071

Ejemplares similares

Case study: New onset of neuropsychiatric symptoms following switching to a dolutegravir regimen
por: Badat, Ahmed, et al.
Publicado: (2022)

Assessing HIV transmission knowledge in psychiatric patients in Johannesburg, South Africa
por: Matodzi, Hangwani J., et al.
Publicado: (2023)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania
por: Mutagonda, Ritah F., et al.
Publicado: (2022)

Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimens
por: Okoli, Chinyere, et al.
Publicado: (2021)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
por: da Silva, Gabriella Jomara, et al.
Publicado: (2023)

Real-World Experience with Dolutegravir-Based Two-Drug Regimens
por: Ward, Douglas, et al.
Publicado: (2020)

Assessing the prevalence of psychotic symptoms in epileptic patients at a tertiary clinic
por: Hungwe, Michelle M., et al.
Publicado: (2023)

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2023)

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
por: Rolle, Charlotte-Paige, et al.
Publicado: (2021)

Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
por: Belay, Yared Belete, et al.
Publicado: (2021)

Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort
por: Bonfanti, Paolo, et al.
Publicado: (2020)

The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India
por: Zheng, Amy, et al.
Publicado: (2018)

Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review
por: Hill, Andrew, et al.
Publicado: (2018)

Assessing the clinical utility of the severity dependence scale for benzodiazepine use disorder
por: Lowton, Karishma, et al.
Publicado: (2021)

Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
por: Priest, Julie, et al.
Publicado: (2023)

Treatment Satisfaction and Its Associated Factors of Dolutegravir Based Regimen in a Resource Limited Setting
por: Mehari, Eden Abetu, et al.
Publicado: (2021)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
por: Fokam, Joseph, et al.
Publicado: (2020)

Assessing attitudes of fourth year medical students towards psychiatry and mental illness
por: Ochse, Stacey L., et al.
Publicado: (2023)

Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV
por: Martínez-Sanz, Javier, et al.
Publicado: (2022)

Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients
por: Punekar, Yogesh Suresh, et al.
Publicado: (2019)

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
por: Quercia, Romina, et al.
Publicado: (2015)

Adherence to Antiretroviral Therapy and Associated Factors Among People Living With HIV Following the Introduction of Dolutegravir Based Regimens in Dar es Salaam, Tanzania
por: Kilapilo, Mary Spicar, et al.
Publicado: (2022)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China
por: Zhong, Mingli, et al.
Publicado: (2023)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)
por: Bousmah, Marwân-al-Qays, et al.
Publicado: (2020)

1586. Impact of Dolutegravir-based Regimen on Metabolic Syndrome and its Components in Adults with HIV in Care at Hospital Roosevelt in Guatemala City
por: Farfán, Alvaro J Mazariegos, et al.
Publicado: (2023)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis
por: Cruciani, Mario, et al.
Publicado: (2019)

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
por: Gil, Horacio, et al.
Publicado: (2022)

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
por: Chapola, John C., et al.
Publicado: (2023)

The role of dolutegravir in the management of HIV infection
por: Miller, Misty M, et al.
Publicado: (2015)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

Depression and diagnosis of neurocognitive impairment in HIV-positive patients
por: Pinheiro, C.A.T., et al.
Publicado: (2016)

Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV
por: Saborido-Alconchel, Abraham, et al.
Publicado: (2023)

Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV
por: Mahale, Prarthana R, et al.
Publicado: (2023)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3i5lg3n6a1dfmj4299kim4v3bk